MOC
H1 2026 report
Revenue
1.86 m PLN
— YoY
Net income
-6.31 m PLN
— YoY
EBITDA
-5.12 m PLN
— YoY
FCF
-12.23 m PLN
— YoY
Summary
Investment thesis
- Strata netto zmniejszona do 6,31 mln zł dzięki redukcji kosztów (wynagrodzenia −47%).
- Niezakończone prace rozwojowe 81,4 mln zł stanowią 72% aktywów i zależą od wyników badań klinicznych.
- Gotówka 24,9 mln zł po emisji serii K (20,1 mln zł); net cash ok. 20,8 mln zł.
- Zapotrzebowanie na ok. 20 mln zł dodatkowego finansowania w I kw. 2027 r.
Read the full analysis
Financial data is open to everyone. The full analysis — management verdict, commentary, risks, and the full narrative — is available after you sign up or log in.
Financials
BETA
MOC · H1 2026
| Metric | H1 2026 | H1 2025 | Δ YoY | YTD 2026 | Δ YoY | Value type | Segment | Conf. |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.86 | — | — | 1.86 | — | reported | — | 1.00 |
| EBITDA | -5.12 | — | — | -5.12 | — | derived | — | 0.70 |
| EBIT | -6.34 | — | — | -6.34 | — | reported | — | 1.00 |
| EBT | -6.31 | — | — | -6.31 | — | reported | — | 1.00 |
| Net income | -6.31 | — | — | -6.31 | — | reported | — | 1.00 |
| EPS (basic) (PLN) | -0.29 | — | — | -0.29 | — | reported | — | 1.00 |
| EPS (diluted) (PLN) | -0.29 | — | — | -0.29 | — | reported | — | 1.00 |
| D&A | 1.22 | — | — | 1.22 | — | reported | — | 1.00 |
| Interest expense | 0.09 | — | — | 0.09 | — | reported | — | 1.00 |
| Income tax | 0 | — | — | 0 | — | reported | — | 1.00 |
| Shares (basic) (m units) | 24.72 | — | — | — | — | reported | — | 0.90 |
| EBIT margin | -340% | — | — | -340% | — | derived | — | 0.70 |
| Net margin | -338.3% | — | — | -338.3% | — | derived | — | 0.70 |
| Cash | 24.91 | — | — | — | — | reported | — | 1.00 |
| Total debt | 4.14 | — | — | — | — | reported | — | 1.00 |
| Net debt | -20.77 | — | — | — | — | derived | — | 0.70 |
| Equity | 101.26 | — | — | — | — | reported | — | 1.00 |
| Total assets | 112.61 | — | — | — | — | reported | — | 1.00 |
| Working capital | 17.08 | — | — | — | — | derived | — | 0.70 |
| Current assets | 25.93 | — | — | — | — | reported | — | 1.00 |
| Current liabilities | 8.86 | — | — | — | — | reported | — | 1.00 |
| Non-current liabilities | 2.49 | — | — | — | — | reported | — | 1.00 |
| Trade receivables | 1.02 | — | — | — | — | reported | — | 1.00 |
| Trade payables | 2.34 | — | — | — | — | reported | — | 1.00 |
| Goodwill | 81.5 | — | — | — | — | reported | — | 1.00 |
| CFO | -1.39 | — | — | -1.39 | — | reported | — | 1.00 |
| CapEx | 10.84 | — | — | 10.84 | — | reported | — | 1.00 |
| FCF | -12.23 | — | — | -12.23 | — | derived | — | 0.70 |
| Current ratio | 2.93x | — | — | — | — | derived | — | 0.70 |
| Debt / equity | 0.04x | — | — | — | — | derived | — | 0.70 |
| Debt / assets | 0.04x | — | — | — | — | derived | — | 0.70 |
| Net debt / equity | -0.21x | — | — | — | — | derived | — | 0.70 |
| Revenue growth (YoY) | -47.1% | — | — | -47.1% | — | derived | — | 0.70 |
| EBIT growth (YoY) | 30.6% | — | — | 30.6% | — | derived | — | 0.70 |
| Net income growth (YoY) | 26% | — | — | 26% | — | derived | — | 0.70 |
| EPS growth (YoY) | 29.3% | — | — | 29.3% | — | derived | — | 0.70 |
H1 2026 · Δ YoY
Revenue
1.86
—
1.86
—
- H1 2025
- —
- YTD 2026
- 1.86
- Δ YoY
- —
EBITDA
-5.12
—
-5.12
—
- H1 2025
- —
- YTD 2026
- -5.12
- Δ YoY
- —
EBIT
-6.34
—
-6.34
—
- H1 2025
- —
- YTD 2026
- -6.34
- Δ YoY
- —
EBT
-6.31
—
-6.31
—
- H1 2025
- —
- YTD 2026
- -6.31
- Δ YoY
- —
Net income
-6.31
—
-6.31
—
- H1 2025
- —
- YTD 2026
- -6.31
- Δ YoY
- —
EPS (basic)
(PLN)
-0.29
—
-0.29
—
- H1 2025
- —
- YTD 2026
- -0.29
- Δ YoY
- —
EPS (diluted)
(PLN)
-0.29
—
-0.29
—
- H1 2025
- —
- YTD 2026
- -0.29
- Δ YoY
- —
D&A
1.22
—
1.22
—
- H1 2025
- —
- YTD 2026
- 1.22
- Δ YoY
- —
Interest expense
0.09
—
0.09
—
- H1 2025
- —
- YTD 2026
- 0.09
- Δ YoY
- —
Income tax
0
—
0
—
- H1 2025
- —
- YTD 2026
- 0
- Δ YoY
- —
Shares (basic)
(m units)
24.72
—
24.72
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
EBIT margin
-340%
—
-340%
—
- H1 2025
- —
- YTD 2026
- -340%
- Δ YoY
- —
Net margin
-338.3%
—
-338.3%
—
- H1 2025
- —
- YTD 2026
- -338.3%
- Δ YoY
- —
Cash
24.91
—
24.91
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Total debt
4.14
—
4.14
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Net debt
-20.77
—
-20.77
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Equity
101.26
—
101.26
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Total assets
112.61
—
112.61
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Working capital
17.08
—
17.08
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Current assets
25.93
—
25.93
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Current liabilities
8.86
—
8.86
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Non-current liabilities
2.49
—
2.49
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Trade receivables
1.02
—
1.02
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Trade payables
2.34
—
2.34
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Goodwill
81.5
—
81.5
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
CFO
-1.39
—
-1.39
—
- H1 2025
- —
- YTD 2026
- -1.39
- Δ YoY
- —
CapEx
10.84
—
10.84
—
- H1 2025
- —
- YTD 2026
- 10.84
- Δ YoY
- —
FCF
-12.23
—
-12.23
—
- H1 2025
- —
- YTD 2026
- -12.23
- Δ YoY
- —
Current ratio
2.93x
—
2.93x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Debt / equity
0.04x
—
0.04x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Debt / assets
0.04x
—
0.04x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Net debt / equity
-0.21x
—
-0.21x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Revenue growth (YoY)
-47.1%
—
-47.1%
—
- H1 2025
- —
- YTD 2026
- -47.1%
- Δ YoY
- —
EBIT growth (YoY)
30.6%
—
30.6%
—
- H1 2025
- —
- YTD 2026
- 30.6%
- Δ YoY
- —
Net income growth (YoY)
26%
—
26%
—
- H1 2025
- —
- YTD 2026
- 26%
- Δ YoY
- —
EPS growth (YoY)
29.3%
—
29.3%
—
- H1 2025
- —
- YTD 2026
- 29.3%
- Δ YoY
- —